ORIGINAL PAPER



Echocardiographic characteristics of patients with SARS-CoV-2 infection

Stephan Stöbe 10 · Sarah Richter · Markus Seige · Sebastian Stehr · Ulrich Laufs 10 · Andreas Hagendorff 10

Received: 16 June 2020 / Accepted: 3 August 2020 / Published online: 14 August 2020 © The Author(s) 2020

Abstract

Background Myocardial involvement induced by SARS-CoV-2 infection might be important for long-term prognosis. The aim of this observational study was to characterize the myocardial effects during SARS-CoV-2 infections by echocardiography. **Results and methods** An extended echocardiographic image acquisition protocol was performed in 18 patients with SARS-CoV-2 infection assessing LV longitudinal, radial, and circumferential deformation including rotation, twist, and untwisting. Furthermore, LV deformation was analyzed in an age-matched control group of healthy individuals (n = 20). The most prevalent finding was a reduced longitudinal strain observed predominantly in more than one basal LV segment (n = 10/14 patients, 71%). This pattern reminded of a "reverse tako-tsubo" morphology that is not typical for other viral myocarditis. Additional findings included a biphasic pattern with maximum post-systolic or negative regional radial strain predominantly basal (n = 5/14 patients, 36%); the absence or dispersion of basal LV rotation (n = 6/14 patients, 43%); a reduced or positive regional circumferential strain in more than one segment (n = 7/14 patients, 50%); a net rotation showing late post-systolic twist or biphasic pattern (n = 8/14 patients, 57%); a net rotation showing polyphasic pattern and/or higher maximum net values during diastole (n = 8/14 patients, 57%).

Conclusion Myocardial involvement due to SARS-CoV-2-infection was highly prevalent in the present cohort—even in patients with mild symptoms. It appears to be characterized by specific speckle tracking deformation abnormalities in the basal LV segments. These data set the stage to prospectively test whether these parameters are helpful for risk stratification and for the long-term follow-up of these patients.

Keywords SARS-CoV-2 · COVID-19 · Myocarditis · Deformation imaging · Myocardial strain · Rotation

Introduction

Coronavirus disease 2019 (COVID-19) is a systemic viral infection caused by SARS-CoV-2 (severe acute respiratory syndrome-coronavirus-2) which may lead to life-threatening severe acute respiratory syndromes, especially in high-risk patients [1–5]. COVID-19 patients showed myocardial involvement which is described as special type of acute myocarditis (AM) [6–10]. Myocardial damage can be caused

- Stephan Stöbe stephan.stoebe@gmx.de
- Department of Cardiology, Leipzig University Hospital, Liebigstr. 20, 04103 Leipzig, Germany
- Department of Internal Medicine I, Martha-Maria Hospital Halle-Dölau, Röntgenstr. 1, 06129 Halle (Saale), Germany
- Department of Anesthesiology and Intensive Care, Leipzig University Hospital, Liebigstr. 20, 04103 Leipzig, Germany

directly by SARS-CoV-2 virus or by immunopathological sequelae of myocardial inflammation [8, 11, 12]. Myocardial involvement documented by increased levels of troponin T and brain-type-natriuretic peptide (NT-pro-BNP) or reduced left-ventricular (LV) ejection fraction (EF) is associated with adverse outcomes and increased mortality [13–16]. Therefore, it seems to be important to focus on the detection of myocardial damage at early stage of SARS-CoV-2-infection.

In addition, residual myocardial damage after recovery of the acute phase of the disease might have a significant impact on the patients' prognosis probably due to SARS-CoV-2 induced myocardial fibrosis.

Currently, cardiac magnetic resonance (CMR) imaging represents the gold standard for the detection of AM [17, 18]. However, the use of CMR is limited by its availability, the risks of viral spread, and the state of the severely ill patients. Thus, imaging modalities like echocardiography might be favored under these conditions, because the



devices are easier to clean and more suitable for repetitive investigations, especially if these patients need to be monitored at intensive-care units or in emergency settings.

The present paper describes the experience at the Leipzig University Hospital in detecting myocardial involvement in SARS-CoV-2-infected patients by echocardiography using a specialized extended imaging and analysis protocol to analyze different components of myocardial deformation [19]. The authors hypothesize that myocardial involvement might be detected by echocardiography due to specific abnormalities of regional LV function in SARS-CoV-2-infected patients.

Methods

During the acute stage of the pandemic in April 2020, transthoracic echocardiography (TTE) was performed in 18 patients with SARS-CoV-2 infection at the Leipzig University Hospital and the Community Hospital Halle (Saale). Symptoms of SARS-CoV-2 patients varied from mild/moderate to severe respiratory symptoms requiring long-term mechanical ventilation. Thus, subgroup analyses were performed in patients with mild/moderate symptoms (no mechanical ventilation, n = 4) and severe symptoms (mechanical ventilation needed, n = 14).

All SARS-CoV-2-infected patients have been treated at isolation wards of different institutions, in which TTE was not routinely performed. After technical allocation of necessary ultrasound equipment, four expert cardiologists have performed bed-side 2D TTE with respect to the analysis of LV deformation by 2D speckle tracking by post-processing. The analysis of LV deformation was performed by two investigators experienced in speckle tracking. LV deformation could not have been analyzed by 3D echocardiography, because bed-side 3D TTE could not be performed at the isolation wards. For the detection of residual myocardial involvement beyond the acute-stage 3D TTE has only been performed in selected patients. Pathological echocardiographic findings were exemplarily confirmed by singular CMR results. Repetitive TTE was performed in three patients. Patient characteristics were collected from medical records, laboratory findings, ECG, and X-ray documentations (Table 1).

Furthermore, LV deformation was analyzed in an agematched control group of healthy individuals (n=20).

All subjects provided informed consent after full explanation of the purpose and order of all procedures. The study complies with the Declaration of Helsinki and the study design was approved by the locally appointed ethics committee (359/18-ek).

Basic echocardiographic examination

TTE was performed using a Vivid S70 or Vivid q ultrasound system with an M5 or M5-S phased array probe (GE Healthcare Vingmed Ultrasound AS, Horten, Norway). Echocardiographic analyses were performed with the EchoPac software (Version 202, GE Healthcare Vingmed Ultrasound AS, Horten, Norway) using the quantitative analysis software package. LV dimensions (M mode and/or 2D measurements), LV volumes and LVEF (by biplane LV planimetry by the modified Simpson's rule), relative wall thickness (RWT), LV mass (LVM) (by the Devereux formula), and LV mass index (LVMI) as well as LV remodeling index (LVRI) were assessed [20]. Diastolic function was characterized by maximum velocities of E and A waves $(V_{\text{max}}E, V_{\text{max}}A), E/A$ ratio, E/E' ratio ($V_{max}E$ and maximum myocardial velocities (E') of the basal mitral annulus), isovolumetric relaxation time (IVRT) obtained by pulsed-wave (PW) tissue Doppler imaging, and left atrial (LA) volumes determined by biplane LA planimetry [21]. Right-ventricular (RV) function was assessed by tricuspid annular plane systolic excursion (TAPSE), pulmonary acceleration time (AccT), and by estimation of systolic pulmonary artery pressure (sPAP) assessed by maximum velocity of tricuspid regurgitation using continuous-wave (CW) Doppler.

Myocardial deformation analysis

Global (GLS) and regional (rLS) longitudinal deformation was assessed by determination of layer strain in all apical views. Global (GCS) and regional (rCS) circumferential layer strain and global (GRS) and regional (rRS) radial strain were determined in apical, mid, and basal parasternal short-axis views. For analysis of rotation and rotation rate (twist and untwisting), only apical short -axis views were accepted, which definitively were within the apical third of the LV. Basal short-axis views required documentation of the LV wall during the complete cardiac cycle. In addition, RV GLS was assessed in apical four-chamber views (4-chV). The endocardial contour was manually adjusted, whereas only segments with accurate tracking by carefully visual evaluation were accepted to exclude imaging artifacts.



Table 1 Patient characteristics, symptoms, laboratory findings, comorbidities, as well as conventional 2D echocardiographic and modern deformation parameters of SARS-CoV-2-patients are shown

| Age (years) 64 ± 19.1 71 ± 15.2 41 ± 11.8 < 0.0 | | COVID-19 $(n = 18)$ | COVID-19: severe $(n = 14)$ | COVID-19: mild $(n=4)$ | p value |
|---|--|------------------------|-----------------------------|------------------------|-----------|
| Temperature (°C) 38.1±.1.1 38.3±.1.1 36.9±.0.3 < 0.0 Oxyga saturation (%) 93±6.7 91±6.6 99±0.8 < 0.0 | Male | 14 (78%) | 11 (79%) | 1 (25%) | 0.90 |
| Oxygen saturation (%) 93±6.7 91±6.6 99±0.8 < 0.0 Respiratory rate (min²¹) 21±6.2 24±5.1 15±3.3 < 0.0 Blood pressure systolic/diastolic (mmHg) 13672±18.7/10.0 13469±21.07.6 14282±10.3/11.5 0.44 Dyspancea 13 (72%) 7 (100%) 655% 0.23 Dyspancea 10 (56%) 5 (71%) 5 (45%) 0.22 Fever 10 (56%) 4 (36%) 6 (55%) 0.83 Feitigue 5 (28%) 3 (34%) 2 (18%) 0.90 Angina pectoris 0 (0%) 0 (0%) 0 (3%) - Leucocytes (exp9fl) 8.6±4.3 8.9±4.5 7.3±3.1 0.52 Cercactive broise (fug/ml) 107±96.9 1313±9.1 17±0.0 0.0 Procalcitonin (ng/ml) 127±49.9 131±9.1 17±0.0 0.0 Creative kinase (fug/ml) 127±42.0 121±2.1 127±2.2 127±2.2 12 12 12 12 12 12 12 12 12 12 < | Age (years) | 64 ± 19.1 | 71 ± 15.2 | 41 ± 11.8 | < 0.05 |
| Respiratory rate (min ⁻¹) Blood pressure systolic/diastolic (mmHg) 136/72 ±18.7/10.0 134/69 ±21.0/7.6 142/82 ±10.3/11.5 0.44 Heart rate (bpm) 89 ±14.8 90 ±15.7 84 ±11.5 0.44 Dyspnoca 13 (72%) 7 (100%) 6 (55%) 0.41 Cough 10 (56%) 13 (36%) 6 (55%) 0.43 Fever 10 (56%) 13 (36%) 6 (55%) 0.23 Fever 10 (56%) 13 (36%) 0 (36%) 0 (36%) 0 (38) | Temperature (°C) | 38.1 ± 1.1 | 38.3 ± 1.1 | 36.9 ± 0.3 | < 0.05 |
| Blood pressure systolic/diastolic (mmHg) 136/72 ± 18.7/10.0 134/69 ± 21.07.6 142/82 ± 10.3/11.5 0.44 Heart rate (hym) 89 ± 14.8 90 ± 15.7 84 ± 11.5 0.47 Dyspnoca 13 (72%) 7 (10%) 6 (55%) 0.44 Cough 10 (56%) 5 (71%) 6 (55%) 0.43 Cough 10 (56%) 3 (43%) 6 (55%) 0.83 Fever 10 (056%) 4 (36%) 6 (55%) 0.83 Falique 5 (28%) 3 (43%) 2 (188%) 0.93 Angina pectoris 0 (0%) 0 (0%) 0 (0%) 0 (0%) − Leucocytes (exp9/1) 8.6 ± 4.3 8.9 ± 4.5 7.3 ± 3.1 0.52 C-reactive protein (mg/1) 107.4 ± 96.9 131.8 ± 91.1 1.7 ± 0.8 0.05 0.05 0.0 Procadicionin (ng/m1) 49 ± 15.4 5.3 ± 15.9 0.05 0.0 0.0 Creatine kinase (µka/1) 3.8 ± 6.6 4.9 ± 7.6 1.1 ± 0.3 0.33 Topopoini (* (pg/m1) 36 ± 23 36 ± 23 3.0 ± 23 0.0 ThyropBNP (pg/m1) 1724 ± 2058 1724 ± 2118 < 5.0 < 0.0 □ Dimer (mg/1) 4.5 ± 5.0 5.2 ± 5.2 0.3 ± 0.03 0.0 □ Dimer (mg/1) 4.5 ± 5.0 5.2 ± 5.2 0.3 ± 0.0 0.0 □ Procayanal artial prillation 4 (22%) 12 (86%) 1 (25%) 0.09 Paroxyanal artial fibrillation 4 (22%) 2 (44%) 0 (0%) 0.7 Peripheral artery disease 2 (11%) 2 (14%) 0 (0%) 0.7 Peripheral artery disease 1 (5%) 1 (7%) 0 (0%) 0.0 Pricardial effusion 4 (22%) 3 (21%) 0 (0%) 0.0 Pricardial effusion 4 (23%) 3 (21%) 0 (0%) 0.0 Pricardial effusion 4 (25%) 3 (21%) 0 (0%) 0.0 Pricardial effusion 4 (25%) 3 (24%) 0 (0%) 0.0 Pricardial effusion 4 (25%) 3 (24%) 0 (0%) 0.0 Pricardial effusion 4 (25%) 3 (24%) 0 (0%) 0.0 Pricardial effusion 4 (25%) 3 (24%) 0 (0%) 0.0 Pricardial effusion 4 (25%) 3 (24%) 0 (0%) 0.0 Pricardial effusion 4 (25%) 3 (25%) 0 (0%) 0 (0%) 0.0 Pricardial effusion 4 (25%) 3 (25%) 0 (0%) 0 (0%) 0.0 Pricardial effusion 4 (25%) 3 (25%) 0 (0%) 0 (0%) 0.0 Pricardial effusion 4 (25%) 0 (25%) 0 (25%) 0 (25%) 0 (2 | Oxygen saturation (%) | 93 ± 6.7 | 91 ± 6.6 | 99 ± 0.8 | < 0.05 |
| Heart rate (bpm) 89 ± 14.8 90 ± 15.7 84 ± 11.5 0.47 Dyspnoea 13 (72%) 7 (100%) 6 (55%) 0.41 Dyspnoea 13 (72%) 7 (100%) 6 (55%) 0.41 Dyspnoea 10 (56%) 5 (71%) 5 (45%) 0.23 Fever 10 (56%) 4 (36%) 6 (55%) 0.83 Faitigue 5 (28%) 3 (43%) 2 (18%) 0.90 Angina poetoris 0.00%) 0.00%) 0.0%) 0.70 Dusterioris 0.00% 0.00%) 0.00%) 0.70 Dusterioris 0.00% 0.00%) 0.00%) 0.00% 0.00 Dusteriority protein (mg/ll) 107.4 ± 96.9 131.8 ± 91.1 1.7 ± 0.8 0.01 Dusteriority protein (mg/ll) 127.8 ± 122.1 127.8 ± 122.3 < 7.0 < 0.05 < 0.05 < 0.05 Dusteriority protein (mg/ll) 3.8 ± 6.6 4.9 ± 7.6 1.1 ± 0.3 0.33 < 0.00 Dusteriority protein (mg/ll) 3.8 ± 6.6 4.9 ± 7.6 1.1 ± 0.3 0.33 < 0.00 Dusteriority protein (mg/ll) 3.5 ± 23 3 ± 23 3 < 3 < 0.00 Dusteriority protein (mg/ll) 3.5 ± 23 3 ± 23 3 < 3 < 0.00 Dusteriority protein (mg/ll) 4.5 ± 5.0 5.2 ± 5.2 0.3 ± 0.03 < 0.00 Dusteriority protein (mg/ll) 4.5 ± 5.0 5.2 ± 5.2 0.3 ± 0.03 < 0.00 Dusteriority protein (mg/ll) 4.5 ± 5.0 5.2 ± 5.2 0.3 ± 0.03 < 0.00 Dusteriority protein (mg/ll) 4.5 ± 5.0 5.2 ± 5.2 0.3 ± 0.03 < 0.00 Dusteriority protein (mg/ll) 4.5 ± 5.0 5.2 ± 5.2 0.3 ± 0.03 < 0.00 Dusteriority protein (mg/ll) 4.5 ± 5.0 5.2 ± 5.2 0.3 ± 0.03 < 0.00 Dusteriority protein (mg/ll) 4.5 ± 5.0 5.2 ± 5.2 0.3 ± 0.03 < 0.00 Dusteriority protein (mg/ll) 4.5 ± 5.0 5.2 ± 5.2 0.3 ± 0.03 < 0.00 Dusteriority protein (mg/ll) 4.5 ± 5.0 5.2 ± 5.2 0.3 ± 0.03 < 0.00 Dusteriority protein (mg/ll) 4.5 ± 5.0 5.2 ± 5.2 0.3 ± 0.03 < 0.00 Dusteriority protein (mg/ll) 4.5 ± 5.0 5.2 ± 5.2 0.3 ± 0.03 < 0.00 Dusteriority disease 2 (11%) 2 (14%) 0 (00%) 0.00% | Respiratory rate (min ⁻¹) | 21 ± 6.2 | 24 ± 5.1 | 15 ± 3.3 | < 0.05 |
| Dyspneca 13 (72%) 7 (100%) 6 (55%) 0.41 Cough 10 (56%) 5 (71%) 5 (45%) 0.23 Fever 10 (56%) 4 (36%) 6 (55%) 0.83 Fatigue 5 (28%) 3 (43%) 2 (18%) 0.90 Angina pectoris 0 (0%) 0 (0%) 0 (%) - Cercactive protein (mg/ll) 107.4±96.9 131.8±91.1 1.7±0.8 <0.0 | Blood pressure systolic/diastolic (mmHg) | $136/72 \pm 18.7/10.0$ | $134/69 \pm 21.0/7.6$ | $142/82 \pm 10.3/11.5$ | 0.44/0.18 |
| Cough 10 (56%) 5 (71%) 5 (45%) 0.23 Fever 10 (56%) 4 (36%) 6 (55%) 0.83 Fatigue 5 (28%) 3 (43%) 2 (18%) 0.99 Angina pectoris 0 (0%) 0 (0%) 0 (%) - Leucocytes (exp9fl) 8.6±4.3 8.9±4.5 7.3±3.1 0.52 Creactive protein (mg/l) 1074±96.9 131.8±9.11. 1.7±0.8 <0.0 | Heart rate (bpm) | 89 ± 14.8 | 90 ± 15.7 | 84 ± 11.5 | 0.47 |
| Fever 10 (56%) 4 (36%) 6 (55%) 0.83 Fairgue 5 (28%) 3 (43%) 2 (18%) 0.90 Angina pectoris 0 (0%) 0 (0%) 0 (0%) 0 (0%) - Leucocytes (exp9/l) 8.6 ± 4.3 8.9 ± 4.5 7.3 ± 3.1 0.52 C-reactive protein (mg/l) 107.4 ± 96.9 131.8 ± 91.1 1.7 ± 0.8 < 0.0 Interleukin-6 (pg/ml) 127.8 ± 122.1 127.8 ± 122.3 < 7.0 < 0.0 Interleukin-6 (pg/ml) 127.8 ± 122.1 127.8 ± 122.3 < 7.0 < 0.0 Interleukin-6 (pg/ml) 3.8 ± 6.6 4.9 ± 7.6 1.1 ± 0.3 0.33 Troponin T (pg/ml) 36 ± 23 36 ± 23 < 3 < 0.0 Interleukin-10 (pg/ml) 172.4 ± 2058 172.4 ± 218 < 50 < 0.0 Interleukin-10 (pg/ml) 172.4 ± 2058 172.4 ± 2118 < 50 < 0.0 Interleukin-10 (pg/ml) 172.4 ± 2058 172.4 ± 2118 < 50 < 0.0 Interleukin-10 (pg/ml) 172.4 ± 2058 172.4 ± 218 < 50 < 0.0 Interleukin-10 (pg/ml) 172.4 ± 2058 172.4 ± 2118 < 50 < 0.0 Interleukin-10 (pg/ml) 172.4 ± 2058 172.4 ± 2118 < 50 < 0.0 Interleukin-10 (pg/ml) 172.4 ± 2058 172.4 ± 2118 < 50 < 0.0 Interleukin-10 (pg/ml) 172.4 ± 2058 172.4 ± 2118 < 50 < 0.0 Interleukin-10 (pg/ml) 172.4 ± 2058 172.4 ± 2118 < 50 < 0.0 Interleukin-10 (pg/ml) 172.4 ± 2058 172.4 ± 2118 < 50 < 0.0 Interleukin-10 (pg/ml) 172.4 ± 2058 172.4 ± 2118 < 50 < 0.0 Interleukin-10 (pg/ml) 172.4 ± 2058 172.4 ± 2118 < 50 < 0.0 Interleukin-10 (pg/ml) 172.4 ± 2058 172.4 ± 218 < 0.0 Interleukin-10 (pg/ml) 172.4 ± 2058 172.4 ± 218 < 0.0 Interleukin-10 (pg/ml) 172.4 ± 2058 172.4 ± 20.0 Interleukin-10 (pg/ml) 172.4 ± 2058 172.4 ± 20.0 Interleukin-10 (pg/ml) 172.4 ± 2058 172.4 ± 20.0 Interleukin-10 (pg/ml) 172.4 | Dyspnoea | 13 (72%) | 7 (100%) | 6 (55%) | 0.41 |
| Fatigue 5 (28%) 3 (43%) 2 (18%) 0.90 Angina pectoris 0 (0%) 0 (0%) 0 (0%) 0 (%) | Cough | 10 (56%) | 5 (71%) | 5 (45%) | 0.23 |
| Angina pectoris $0(0\%)$ $0(0\%)$ $0(\%)$ $0(\%)$ $-$ Leucocytes (exp9/l) 8.6 ± 4.3 8.9 ± 4.5 7.3 ± 3.1 0.52 $-$ Creactive protein (mg/l) 107.4 ± 96.9 131.8 ± 91.1 1.7 ± 0.8 <0.05 <0.05 could from the protein (mg/l) 4.9 ± 15.4 5.3 ± 15.9 <0.05 <0.05 could interleukin-6 (pg/ml) 127.8 ± 122.1 127.8 ± 122.3 <7.0 <0.0 <0.0 Interleukin-6 (pg/ml) 3.8 ± 6.6 4.9 ± 7.6 1.1 ± 0.3 0.33 <0.0 <0.0 <0.0 <0.0 <0.0 <0.0 <0.0 <0.0 <0.0 <0.0 <0.0 <0.0 <0.0 <0.0 <0.0 <0.0 <0.0 <0.0 <0.0 <0.0 <0.0 <0.0 <0.0 <0.0 <0.0 <0.0 <0.0 <0.0 <0.0 <0.0 <0.0 <0.0 <0.0 <0.0 <0.0 <0.0 <0.0 <0.0 <0.0 <0.0 <0.0 <0.0 <0.0 <0.0 <0.0 <0.0 <0.0 <0.0 <0.0 <0.0 <0.0 <0.0 <0.0 <0.0 <0.0 <0.0 <0.0 <0.0 <0.0 <0.0 <0.0 <0.0 <0.0 <0.0 <0.0 <0.0 <0.0 <0.0 <0.0 <0.0 <0.0 <0.0 <0.0 <0.0 <0.0 <0.0 <0.0 <0.0 <0.0 <0.0 <0.0 <0.0 <0.0 <0.0 <0.0 <0.0 <0.0 <0.0 <0.0 <0.0 <0.0 <0.0 <0.0 <0.0 <0.0 <0.0 <0.0 <0.0 <0.0 <0.0 <0.0 <0.0 <0.0 <0.0 <0.0 <0.0 <0.0 <0.0 <0.0 <0.0 <0.0 <0.0 <0.0 <0.0 <0.0 <0.0 <0.0 <0.0 <0.0 <0.0 <0.0 <0.0 <0.0 <0.0 <0.0 <0.0 <0.0 <0.0 <0.0 <0.0 <0.0 <0.0 <0.0 <0.0 <0.0 <0.0 <0.0 <0.0 <0.0 <0.0 <0.0 <0.0 <0.0 <0.0 <0.0 <0.0 <0.0 <0.0 <0.0 <0.0 <0.0 <0.0 <0.0 <0.0 <0.0 <0.0 <0.0 <0.0 <0.0 <0.0 <0.0 <0.0 <0.0 <0.0 <0.0 <0.0 <0.0 <0.0 <0.0 <0.0 <0.0 <0.0 <0.0 <0.0 <0.0 <0.0 <0.0 <0.0 <0.0 <0.0 <0.0 <0.0 <0.0 <0.0 <0.0 <0.0 <0.0 <0.0 <0.0 <0.0 <0.0 <0.0 <0.0 <0.0 <0.0 <0.0 <0.0 <0.0 <0.0 <0.0 <0.0 <0.0 <0.0 <0.0 <0.0 <0.0 <0.0 <0.0 <0.0 <0.0 <0.0 <0.0 <0.0 <0.0 <0.0 <0.0 <0.0 <0.0 <0.0 <0.0 <0.0 <0.0 <0.0 <0.0 <0.0 <0.0 <0.0 <0.0 <0.0 <0.0 <0.0 <0.0 <0.0 <0.0 <0.0 <0.0 | Fever | 10 (56%) | 4 (36%) | 6 (55%) | 0.83 |
| Leucocytes (exp9/l) | Fatigue | 5 (28%) | 3 (43%) | 2 (18%) | 0.90 |
| C-reactive protein (mg/ln) 107.4 ± 96.9 131.8 ± 91.1 1.7 ± 0.8 < 0.05 Procalcitorin (ng/ml) 4.9 ± 15.4 5.3 ± 15.9 < 0.05 < 0.05 Interleukin-6 (pg/ml) 127.8 ± 122.1 127.8 ± 122.3 < 7.0 < 0.05 Creatine kinase (µkat/l) 3.8 ± 6.6 4.9 ± 7.6 1.1 ± 0.3 < 0.35 Troponin T (pg/ml) 3.6 ± 23 3.6 ± 23 < 3 < 0.05 NT-proBNP (pg/ml) 1724 ± 2088 1724 ± 2118 < 50 < 0.05 D-Dimer (mg/l) 4.5 ± 5.0 5.2 ± 5.2 0.3 ± 0.03 < 0.05 Arterial hypertension 13 (72%) 12 (86%) 1 (25%) < 0.05 Paroxysmal atrial fibrillation 4 (22%) 4 (29%) 0 (0%) < 0.06 Valvular heart disease (> moderate) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) | Angina pectoris | 0 (0%) | 0 (0%) | 0 (%) | _ |
| Procalcitonin (ng/ml) 4.9 ± 15.4 5.3 ± 15.9 < 0.05 < 0.01 Interleukin-6 (pg/ml) 127.8 ± 122.1 127.8 ± 122.3 < 7.0 | Leucocytes (exp9/l) | 8.6 ± 4.3 | 8.9 ± 4.5 | 7.3 ± 3.1 | 0.52 |
| $ \begin{array}{c ccccccccccccccccccccccccccccccccccc$ | C-reactive protein (mg/l) | 107.4 ± 96.9 | 131.8 ± 91.1 | 1.7 ± 0.8 | < 0.05 |
| Creatine kinase (µkat/l) 3.8 ± 6.6 4.9 ± 7.6 1.1 ± 0.3 0.33 Troponin T (pg/ml) 36 ± 23 36 ± 23 <3 <0.0 NT-proBNP (pg/ml) 1724 ± 2058 1724 ± 2118 <50 <0.0 D-Dimer (mg/l) 4.5 ± 5.0 5.2 ± 5.2 0.3 ± 0.03 <0.0 Arterial hypertension 13 (72%) 12 (86%) 1 (25%) <0.09 Paroxysmal atrial fibrillation 4 (22%) 4 (29%) $<0.0\%$ $<0.0\%$ Valvular heart disease (> moderate) $<0.0\%$ $<0.0\%$ $<0.0\%$ $<0.0\%$ Valvular heart disease (> moderate) $<0.0\%$ $<0.0\%$ $<0.0\%$ $<0.0\%$ $<0.0\%$ $<0.0\%$ $<0.0\%$ $<0.0\%$ $<0.0\%$ $<0.0\%$ $<0.0\%$ $<0.0\%$ $<0.0\%$ $<0.0\%$ $<0.0\%$ $<0.0\%$ $<0.0\%$ $<0.0\%$ $<0.0\%$ $<0.0\%$ $<0.0\%$ $<0.0\%$ $<0.0\%$ $<0.0\%$ $<0.0\%$ $<0.0\%$ $<0.0\%$ $<0.0\%$ $<0.0\%$ $<0.0\%$ $<0.0\%$ $<0.0\%$ $<0.0\%$ | Procalcitonin (ng/ml) | 4.9 ± 15.4 | 5.3 ± 15.9 | < 0.05 | < 0.05 |
| $ \begin{array}{cccccccccccccccccccccccccccccccccccc$ | Interleukin-6 (pg/ml) | 127.8 ± 122.1 | 127.8 ± 122.3 | < 7.0 | < 0.05 |
| NT-proBNP (pg/ml) 1724±2058 1724±2118 < 50 < 0.0 p-Dimer (mg/l) 4.5±5.0 5.2±5.2 0.3±0.03 < 0.0 Arterial hypertension 13 (72%) 12 (86%) 1 (25%) 0.09 Paroxysmal atrial fibrillation 4 (22%) 4 (29%) 0 (0%) < 0.0 Valvular heart disease (> moderate) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0.17 Myocardial infarction 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0.17 Myocardial infarction 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0.17 Myocardial infarction 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0.17 Myocardial infarction 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0.17 Myocardial infarction 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0.17 Myocardial infarction 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0.17 Myocardial infarction 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0.17 Myocardial infarction 0 (0%) 0 (0%) 0 (0%) 0.17 Myocardial infarction 0 (0%) 0 (0%) 0 (0%) 0.17 Myocardial infarction 0 (0%) 0 (0%) 0 (0%) 0.19 Myocardial infarction 0 (0%) 0 (0%) 0 (0%) 0.19 Myocardial infarction 0 (0%) 0 (0%) 0 (0%) 0.19 Myocardial infarction 0 (0%) 0 | Creatine kinase (µkat/l) | 3.8 ± 6.6 | 4.9 ± 7.6 | 1.1 ± 0.3 | 0.33 |
| p-Dimer (mg/l) 4.5 \pm 5.0 5.2 \pm 5.2 0.3 \pm 0.03 <0.03 <0.04 Arterial hypertension 13 (72%) 12 (86%) 1 (25%) 0.09 Paroxysmal atrial fibrillation 4 (22%) 4 (29%) 0 (0%) 0.0% <0.00 | Troponin T (pg/ml) | 36 ± 23 | 36 ± 23 | < 3 | < 0.05 |
| Arterial hypertension $13 (72\%)$ $12 (86\%)$ $1 (25\%)$ 0.09 Paroxysmal atrial fibrillation $4 (22\%)$ $4 (29\%)$ $0 (0\%)$ 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.17 Myocardial infarction 0.0% | NT-proBNP (pg/ml) | 1724 ± 2058 | 1724 ± 2118 | < 50 | < 0.05 |
| Paroxysmal atrial fibrillation 4 (22%) 4 (29%) 0 (0%) < 0.00 | D-Dimer (mg/l) | 4.5 ± 5.0 | 5.2 ± 5.2 | 0.3 ± 0.03 | < 0.05 |
| Valvular heart disease (> moderate) 0 (0%) 0 (0%) 0 (0%) - Coronary artery disease 2 (11%) 2 (14%) 0 (0%) 0.17 Myocardial infarction 0 (0%) 0 (0%) 0 (0%) - Peripheral artery disease 3 (17%) 3 (21%) 0 (0%) 0.17 Dyslipidemia 4 (22%) 3 (21%) 1 (25%) 0.90 Diabetes mellitus 5 (28%) 4 (29%) 1 (25%) 0.48 Chronic kidney disease <g2 (according="" kdigo)<="" td="" to=""> 7 (39%) 7 (50%) 0 (0%) <0.48</g2> | Arterial hypertension | 13 (72%) | 12 (86%) | 1 (25%) | 0.09 |
| Coronary artery disease 2 (11%) 2 (14%) 0 (0%) 0.17 Myocardial infarction 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) Peripheral artery disease 3 (17%) 3 (21%) 0 (0%) 0.17 Dyslipidemia 4 (22%) 3 (21%) 1 (25%) 0.90 Diabetes mellitus 5 (28%) 4 (29%) 1 (25%) 0.90 Chronic kidney disease < G2 (according to KDIGO) | Paroxysmal atrial fibrillation | 4 (22%) | 4 (29%) | 0 (0%) | < 0.05 |
| Myocardial infarction 0 (0%) 0 (0%) 0 (0%) - Peripheral artery disease 3 (17%) 3 (21%) 0 (0%) 0.17 Dyslipidemia 4 (22%) 3 (21%) 1 (25%) 0.90 Diabetes mellitus 5 (28%) 4 (29%) 1 (25%) 0.48 Chronic kidney disease < G2 (according to KDIGO) | Valvular heart disease (> moderate) | 0 (0%) | 0 (0%) | 0 (0%) | _ |
| Peripheral artery disease $3 (17\%)$ $3 (21\%)$ $0 (0\%)$ 0.17 Dyslipidemia $4 (22\%)$ $3 (21\%)$ $1 (25\%)$ 0.90 Diabetes mellitus $5 (28\%)$ $4 (29\%)$ $1 (25\%)$ 0.48 Chronic kidney disease $< G2$ (according to KDIGO) $7 (39\%)$ $7 (50\%)$ $0 (0\%)$ < 0.40 Chronic obstructive pulmonary disease $1 (5\%)$ $1 (7\%)$ $0 (0\%)$ 0.39 Stroke $3 (17\%)$ $3 (21\%)$ $0 (0\%)$ 0.90 Pericardial effusion $1 (5\%)$ $1 (7\%)$ $0 (0\%)$ 0.99 Pericardial effusion $1 (5\%)$ $1 (7\%)$ $0 (0\%)$ 0.99 Pleural effusion $1 (5\%)$ $1 (7\%)$ $0 (0\%)$ 0.99 Max. left atrial volume index (ml/m²) $2 (11\%)$ $2 (14\%)$ $0 (0\%)$ 0.19 Max. left atrial volume index (ml/m²) $2 (2\pm 9.4)$ $2 (4\pm 9.7)$ 15 ± 4.2 < 0.14 Relative wall thickness (RWT) $0 (45\pm 0.04)$ $0 (46\pm 0.02)$ $0 (43\pm 0.07)$ $0 (46)$ Left-ventricular mass index $(g/m²)$ 97 ± 19.0 103 ± 16.8 76 ± 6.3 < 0.01 Left-ventricular end-diastolic volume (ml/m²) 47 ± 11.5 47 ± 12.2 46 ± 10.3 0.69 Left-ventricular end-diastolic volume (ml/m²) 47 ± 11.5 47 ± 12.2 46 ± 10.3 0.69 Left-ventricular end-diastolic resource (mm) 62 ± 6.5 63 ± 6.7 58 ± 4.9 0.16 E/A ratio 0.95 ± 0.3 0.88 ± 0.2 1.15 ± 0.3 0.15 Left-ventricular end-diastolic pressure E/e' 8.6 ± 2.6 9.2 ± 2.6 6.7 ± 1.6 0.15 Mitral annular plain systolic excursion (mm) 12 ± 2.2 12 ± 2.3 13 ± 1.7 0.72 Tricuspid annular plain systolic excursion (mm) 12 ± 2.2 12 ± 2.3 13 ± 1.7 0.72 Tricuspid annular plain systolic excursion (mm) 22 ± 3.2 22 ± 3.5 22 ± 2.4 0.89 Pulmonary acceleration time (s) 111 ± 19.9 107 ± 19.9 124 ± 14.9 0.11 Systolic pulmonary artery pressure (mmHg) 26 ± 8.7 26 ± 9.2 26 ± 7.8 0.95 | Coronary artery disease | 2 (11%) | 2 (14%) | 0 (0%) | 0.17 |
| $\begin{array}{cccccccccccccccccccccccccccccccccccc$ | Myocardial infarction | 0 (0%) | 0 (0%) | 0 (0%) | _ |
| Diabetes mellitus $5 (28\%)$ $4 (29\%)$ $1 (25\%)$ 0.48 Chronic kidney disease $<$ G2 (according to KDIGO) $7 (39\%)$ $7 (50\%)$ $0 (0\%)$ < 0.05 Chronic obstructive pulmonary disease $1 (5\%)$ $1 (7\%)$ $0 (0\%)$ 0.39 Stroke $3 (17\%)$ $3 (21\%)$ $0 (0\%)$ 0.39 Pericardial effusion $1 (5\%)$ $1 (7\%)$ $0 (0\%)$ 0.39 Pleural effusion $2 (11\%)$ $2 (14\%)$ $0 (0\%)$ 0.39 Pleural effusion $2 (11\%)$ $2 (14\%)$ $0 (0\%)$ 0.39 Max. left atrial volume index (ml/m^2) 22 ± 9.4 24 ± 9.7 15 ± 4.2 0.09 Relative wall thickness (RWT) 0.45 ± 0.04 0.46 ± 0.02 0.43 ± 0.07 0.46 Left-ventricular mass index (g/m^2) 97 ± 19.0 103 ± 16.8 76 ± 6.3 0.09 Left-ventricular remodeling index (g/ml) 2.2 ± 0.7 2.3 ± 0.7 1.7 ± 0.3 0.69 Left-ventricular end-diastolic volume (ml/m^2) 47 ± 11.5 47 ± 12.2 46 ± 10.3 0.69 Left-ventricular end-diastolic volume (ml/m^2) 47 ± 11.5 47 ± 12.2 46 ± 10.3 0.69 Left-ventricular end-diastolic pressure E/e' 8.6 ± 2.6 9.2 ± 2.6 6.7 ± 1.6 0.15 Left-ventricular end-diastolic pressure E/e' 8.6 ± 2.6 9.2 ± 2.6 6.7 ± 1.6 0.15 Mitral annular plain systolic excursion (mm) 12 ± 2.2 12 ± 2.3 13 ± 1.7 0.72 Tricuspid annular plain systolic excursion (mm) 12 ± 2.2 12 ± 2.3 13 ± 1.7 0.72 Tricuspid annular plain systolic excursion (mm) 12 ± 2.2 12 ± 2.3 13 ± 1.7 0.72 Pulmonary acceleration time (s) 111 ± 19.9 107 ± 19.9 124 ± 14.9 0.11 Systolic pulmonary artery pressure (mmHg) 26 ± 8.7 26 ± 9.2 26 ± 7.8 0.95 | Peripheral artery disease | 3 (17%) | 3 (21%) | 0 (0%) | 0.17 |
| Chronic kidney disease $<$ G2 (according to KDIGO) 7 (39%) 7 (50%) 0 (0%) $<$ 0.07 (Chronic obstructive pulmonary disease 1 (5%) 1 (7%) 0 (0%) 0.39 (50 (5%)) 1 (7%) 0 (0%) 0.39 (50 (5%)) 1 (7%) 0 (0%) 0.39 (50 (5%)) 1 (7%) 0 (0%) 0.39 (50 (5%)) 1 (7%) 0 (0%) 0.39 (50 (5%)) 1 (7%) 0 (0%) 0.39 (50 (5%)) 1 (7%) 0 (0%) 0.39 (50 (5%)) 1 (7%) 0 (0%) 0.39 (50 (5%)) 1 (7%) 0 (0%) 0.39 (50 (5%)) 1 (7%) 0 (0%) 0.39 (50 (5%)) 1 (7%) 0 (0%) 0.39 (50 (5%)) 1 (7%) 0 (0%) 0.39 (50 (5%)) 1 (7%) 0 (0%) 0.39 (50 (5%)) 1 (7%) 0 (0%) 0 (0%) 0.39 (50 (5%)) 1 (7%) 0 (0%) 0 (0%) 0.39 (50 (5%)) 1 (7%) 0 (0%) 0 (0%) 0.39 (50 (5%)) 1 (7%) 0 (0%) 0 (0%) 0.39 (50 (5%)) 1 (7%) 0 (0%) 0 (0%) 0.39 (50 (5%)) 1 (7%) 0 (0%) 0 (0%) 0.39 (50 (5%)) 1 (7%) 0 (0%) 0 (0%) 0.39 (50 (5%)) 1 (7%) 0 (0%) 0 (0%) 0.39 (50 (5%)) 1 (7%) 0 (0%) 0 (0%) 0.39 (5%) 0 (0%) 0 (0%) 0.39 (5%) 0 (0%) 0 (0%) 0.39 (5%) 0 (0%) 0 (0%) 0 (0%) 0.39 (5%) 0 (0%) 0 (0%) 0 (0%) 0.39 (5%) 0 (0 | Dyslipidemia | 4 (22%) | 3 (21%) | 1 (25%) | 0.90 |
| Chronic obstructive pulmonary disease $1 (5\%)$ $1 (7\%)$ $0 (0\%)$ 0.39 Stroke $3 (17\%)$ $3 (21\%)$ $0 (0\%)$ 0.09 Pericardial effusion $1 (5\%)$ $1 (7\%)$ $0 (0\%)$ 0.09 Peural effusion $2 (11\%)$ $2 (14\%)$ $0 (0\%)$ 0.39 Max. left atrial volume index (ml/m²) 22 ± 9.4 24 ± 9.7 15 ± 4.2 <0.4 Relative wall thickness (RWT) 0.45 ± 0.04 0.46 ± 0.02 0.43 ± 0.07 0.46 Left-ventricular mass index (g/m²) 97 ± 19.0 103 ± 16.8 76 ± 6.3 <0.4 Left-ventricular remodeling index (g/ml) 2.2 ± 0.7 2.3 ± 0.7 1.7 ± 0.3 <0.4 Indexed left-ventricular end-diastolic volume (ml/m²) 47 ± 11.5 47 ± 12.2 46 ± 10.3 0.69 Left-ventricular end-diastolic volume (ml/m²) 47 ± 11.5 47 ± 12.2 46 ± 10.3 0.69 Left-ventricular end-diastolic pressure E/e' 8.6 ± 2.6 9.2 ± 2.6 6.7 ± 1.6 <0.1 Isovolumetric relaxation time (s) 69 ± 19.4 65 ± 18.6 82 ± 18.4 0.17 Mitral annular plain systolic excursion (mm) 12 ± 2.2 12 ± 2.3 13 ± 1.7 0.72 Tricuspid annular plain systolic excursion (mm) 22 ± 3.2 22 ± 3.5 22 ± 2.4 0.89 Pulmonary acceleration time (s) 111 ± 19.9 107 ± 19.9 124 ± 14.9 0.11 Systolic pulmonary artery pressure (mmHg) 26 ± 8.7 26 ± 9.2 26 ± 7.8 0.95 | Diabetes mellitus | 5 (28%) | 4 (29%) | 1 (25%) | 0.48 |
| Stroke 3 (17%) 3 (21%) 0 (0%) 0.09 Pericardial effusion 1 (5%) 1 (7%) 0 (0%) 0.39 Pleural effusion 2 (11%) 2 (14%) 0 (0%) 0.19 Max. left atrial volume index (ml/m²) 22 ± 9.4 24 ± 9.7 15 ± 4.2 <0.0 Max. left atrial volume index (ml/m²) 0.45 ± 0.04 0.46 ± 0.02 0.43 ± 0.07 0.46 Relative wall thickness (RWT) 0.45 ± 0.04 0.46 ± 0.02 0.43 ± 0.07 0.46 Left-ventricular mass index (g/m²) 97 ± 19.0 103 ± 16.8 76 ± 6.3 <0.0 Left-ventricular mass index (g/m²) 97 ± 19.0 103 ± 16.8 76 ± 6.3 <0.0 Left-ventricular remodeling index (g/ml) 2.2 ± 0.7 2.3 ± 0.7 1.7 ± 0.3 <0.0 Indexed left-ventricular end-diastolic volume (ml/m²) 47 ± 11.5 47 ± 12.2 46 ± 10.3 0.69 Left-ventricular end-diastolic pressure E/e' 8.6 ± 2.6 63 ± 6.7 58 ± 4.9 0.16 Isovolumetric relaxation time (s) 69 ± 19.4 65 ± 18.6 82 ± 18.4 0.17 | Chronic kidney disease < G2 (according to KDIGO) | 7 (39%) | 7 (50%) | 0 (0%) | < 0.05 |
| Pericardial effusion $1 (5\%)$ $1 (7\%)$ $0 (0\%)$ 0.39 Pleural effusion $2 (11\%)$ $2 (14\%)$ $0 (0\%)$ 0.19 Max. left atrial volume index (ml/m²) 22 ± 9.4 24 ± 9.7 15 ± 4.2 0.49 Relative wall thickness (RWT) 0.45 ± 0.04 0.46 ± 0.02 0.43 ± 0.07 0.46 Left-ventricular mass index (g/m²) 97 ± 19.0 103 ± 16.8 76 ± 6.3 0.49 Left-ventricular remodeling index (g/ml) 0.22 ± 0.7 0.39 ± 0.7 0.39 Indexed left-ventricular end-diastolic volume (ml/m²) 0.39 ± 0.79 0.39 | Chronic obstructive pulmonary disease | 1 (5%) | 1 (7%) | 0 (0%) | 0.39 |
| Pleural effusion $2 (11\%)$ $2 (14\%)$ $0 (0\%)$ 0.19 Max. left atrial volume index (ml/m²) 22 ± 9.4 24 ± 9.7 15 ± 4.2 <0.0 Relative wall thickness (RWT) 0.45 ± 0.04 0.46 ± 0.02 0.43 ± 0.07 0.46 Left-ventricular mass index (g/m²) 97 ± 19.0 103 ± 16.8 76 ± 6.3 <0.0 Left-ventricular remodeling index (g/ml) 2.2 ± 0.7 2.3 ± 0.7 1.7 ± 0.3 <0.1 Indexed left-ventricular end-diastolic volume (ml/m²) 47 ± 11.5 47 ± 12.2 46 ± 10.3 0.69 Left-ventricular ejection fraction (%) 62 ± 6.5 63 ± 6.7 58 ± 4.9 0.16 E/A ratio 0.95 ± 0.3 0.88 ± 0.2 1.15 ± 0.3 0.15 Left-ventricular end-diastolic pressure E/e' 8.6 ± 2.6 9.2 ± 2.6 6.7 ± 1.6 <0.4 Isovolumetric relaxation time (s) 69 ± 19.4 65 ± 18.6 82 ± 18.4 0.17 Mitral annular plain systolic excursion (mm) 12 ± 2.2 12 ± 2.3 13 ± 1.7 0.72 Tricuspid annular plain systolic excursion (mm) 22 ± 3.2 22 ± 3.5 22 ± 2.4 0.89 Pulmonary acceleration time (s) 111 ± 19.9 107 ± 19.9 124 ± 14.9 0.11 Systolic pulmonary artery pressure (mmHg) 26 ± 8.7 26 ± 9.2 26 ± 7.8 0.95 | Stroke | 3 (17%) | 3 (21%) | 0 (0%) | 0.09 |
| Max. left atrial volume index (ml/m²) 22 ± 9.4 24 ± 9.7 15 ± 4.2 <0.0 Relative wall thickness (RWT) 0.45 ± 0.04 0.46 ± 0.02 0.43 ± 0.07 0.46 Left-ventricular mass index (g/m²) 97 ± 19.0 103 ± 16.8 76 ± 6.3 <0.0 Left-ventricular remodeling index (g/ml) 2.2 ± 0.7 2.3 ± 0.7 1.7 ± 0.3 <0.0 Indexed left-ventricular end-diastolic volume (ml/m²) 47 ± 11.5 47 ± 12.2 46 ± 10.3 0.69 Left-ventricular ejection fraction (%) 62 ± 6.5 63 ± 6.7 58 ± 4.9 0.16 Left-ventricular end-diastolic pressure E/e' 8.6 ± 2.6 9.2 ± 2.6 6.7 ± 1.6 <0.0 Isovolumetric relaxation time (s) 69 ± 19.4 65 ± 18.6 82 ± 18.4 0.17 Mitral annular plain systolic excursion (mm) 12 ± 2.2 12 ± 2.3 13 ± 1.7 0.72 Tricuspid annular plain systolic excursion (mm) 22 ± 3.2 22 ± 3.5 22 ± 2.4 0.89 Pulmonary acceleration time (s) 111 ± 19.9 107 ± 19.9 124 ± 14.9 0.11 Systolic pulmonary artery pressure (mmHg) 26 ± 8.7 | Pericardial effusion | 1 (5%) | 1 (7%) | 0 (0%) | 0.39 |
| Relative wall thickness (RWT) 0.45 ± 0.04 0.46 ± 0.02 0.43 ± 0.07 0.46 Left-ventricular mass index (g/m²) 97 ± 19.0 103 ± 16.8 76 ± 6.3 < 0.00 Left-ventricular remodeling index (g/ml) 2.2 ± 0.7 2.3 ± 0.7 1.7 ± 0.3 < 0.00 Indexed left-ventricular end-diastolic volume (ml/m²) 47 ± 11.5 47 ± 12.2 46 ± 10.3 0.69 Left-ventricular ejection fraction (%) 62 ± 6.5 63 ± 6.7 58 ± 4.9 0.16 E/A ratio 0.95 ± 0.3 0.88 ± 0.2 1.15 ± 0.3 0.15 Left-ventricular end-diastolic pressure E/e' 8.6 ± 2.6 9.2 ± 2.6 6.7 ± 1.6 < 0.00 Isovolumetric relaxation time (s) 69 ± 19.4 65 ± 18.6 82 ± 18.4 0.17 Mitral annular plain systolic excursion (mm) 12 ± 2.2 12 ± 2.3 13 ± 1.7 0.72 Tricuspid annular plain systolic excursion (mm) 22 ± 3.2 22 ± 3.5 22 ± 2.4 0.89 Pulmonary acceleration time (s) 111 ± 19.9 107 ± 19.9 124 ± 14.9 0.11 Systolic pulmonary artery pressure (mmHg) 26 ± 8.7 | Pleural effusion | 2 (11%) | 2 (14%) | 0 (0%) | 0.19 |
| Left-ventricular mass index (g/m²) 97 ± 19.0 103 ± 16.8 76 ± 6.3 < 0.0 Left-ventricular remodeling index (g/ml) 2.2 ± 0.7 2.3 ± 0.7 1.7 ± 0.3 < 0.0 Indexed left-ventricular end-diastolic volume (ml/m²) 47 ± 11.5 47 ± 12.2 46 ± 10.3 0.69 Left-ventricular ejection fraction (%) 62 ± 6.5 63 ± 6.7 58 ± 4.9 0.16 E/A ratio 0.95 ± 0.3 0.88 ± 0.2 1.15 ± 0.3 0.15 Left-ventricular end-diastolic pressure E/e' 8.6 ± 2.6 9.2 ± 2.6 6.7 ± 1.6 < 0.0 Isovolumetric relaxation time (s) 69 ± 19.4 65 ± 18.6 82 ± 18.4 0.17 Mitral annular plain systolic excursion (mm) 12 ± 2.2 12 ± 2.3 13 ± 1.7 0.72 Tricuspid annular plain systolic excursion (mm) 22 ± 3.2 22 ± 3.5 22 ± 2.4 0.89 Pulmonary acceleration time (s) 111 ± 19.9 107 ± 19.9 124 ± 14.9 0.11 Systolic pulmonary artery pressure (mmHg) 26 ± 8.7 26 ± 9.2 26 ± 7.8 0.95 | Max. left atrial volume index (ml/m²) | 22 ± 9.4 | 24 ± 9.7 | 15 ± 4.2 | < 0.05 |
| Left-ventricular remodeling index (g/ml) 2.2 ± 0.7 2.3 ± 0.7 1.7 ± 0.3 < 0.0 Indexed left-ventricular end-diastolic volume (ml/m²) 47 ± 11.5 47 ± 12.2 46 ± 10.3 0.69 Left-ventricular ejection fraction (%) 62 ± 6.5 63 ± 6.7 58 ± 4.9 0.16 E/A ratio 0.95 ± 0.3 0.88 ± 0.2 1.15 ± 0.3 0.15 Left-ventricular end-diastolic pressure E/e' 8.6 ± 2.6 9.2 ± 2.6 6.7 ± 1.6 < 0.0 Isovolumetric relaxation time (s) 69 ± 19.4 65 ± 18.6 82 ± 18.4 0.17 Mitral annular plain systolic excursion (mm) 12 ± 2.2 12 ± 2.3 13 ± 1.7 0.72 Tricuspid annular plain systolic excursion (mm) 22 ± 3.2 22 ± 3.5 22 ± 2.4 0.89 Pulmonary acceleration time (s) 111 ± 19.9 107 ± 19.9 124 ± 14.9 0.11 Systolic pulmonary artery pressure (mmHg) 26 ± 8.7 26 ± 9.2 26 ± 7.8 0.95 | Relative wall thickness (RWT) | 0.45 ± 0.04 | 0.46 ± 0.02 | 0.43 ± 0.07 | 0.46 |
| Indexed left-ventricular end-diastolic volume (ml/m²) 47 ± 11.5 47 ± 12.2 46 ± 10.3 0.69 Left-ventricular ejection fraction (%) 62 ± 6.5 63 ± 6.7 58 ± 4.9 0.16 E/A ratio 0.95 ± 0.3 0.88 ± 0.2 1.15 ± 0.3 0.15 Left-ventricular end-diastolic pressure E/e' 8.6 ± 2.6 9.2 ± 2.6 6.7 ± 1.6 < 0.0 Isovolumetric relaxation time (s) 69 ± 19.4 65 ± 18.6 82 ± 18.4 0.17 Mitral annular plain systolic excursion (mm) 12 ± 2.2 12 ± 2.3 13 ± 1.7 0.72 Tricuspid annular plain systolic excursion (mm) 22 ± 3.2 22 ± 3.5 22 ± 2.4 0.89 Pulmonary acceleration time (s) 111 ± 19.9 107 ± 19.9 124 ± 14.9 0.11 Systolic pulmonary artery pressure (mmHg) 26 ± 8.7 26 ± 9.2 26 ± 7.8 0.95 | Left-ventricular mass index (g/m²) | 97 ± 19.0 | 103 ± 16.8 | 76 ± 6.3 | < 0.05 |
| Left-ventricular ejection fraction (%) 62 ± 6.5 63 ± 6.7 58 ± 4.9 0.16 E/A ratio 0.95 ± 0.3 0.88 ± 0.2 1.15 ± 0.3 0.15 Left-ventricular end-diastolic pressure E/e' 8.6 ± 2.6 9.2 ± 2.6 6.7 ± 1.6 <0.0 Isovolumetric relaxation time (s) 69 ± 19.4 65 ± 18.6 82 ± 18.4 0.17 Mitral annular plain systolic excursion (mm) 12 ± 2.2 12 ± 2.3 13 ± 1.7 0.72 Tricuspid annular plain systolic excursion (mm) 22 ± 3.2 22 ± 3.5 22 ± 2.4 0.89 Pulmonary acceleration time (s) 111 ± 19.9 107 ± 19.9 124 ± 14.9 0.11 Systolic pulmonary artery pressure (mmHg) 26 ± 8.7 26 ± 9.2 26 ± 7.8 0.95 | Left-ventricular remodeling index (g/ml) | 2.2 ± 0.7 | 2.3 ± 0.7 | 1.7 ± 0.3 | < 0.05 |
| E/A ratio 0.95 ± 0.3 0.88 ± 0.2 1.15 ± 0.3 0.15 Left-ventricular end-diastolic pressure E/e' 8.6 ± 2.6 9.2 ± 2.6 6.7 ± 1.6 < 0.00 Isovolumetric relaxation time (s) 69 ± 19.4 65 ± 18.6 82 ± 18.4 0.17 Mitral annular plain systolic excursion (mm) 12 ± 2.2 12 ± 2.3 13 ± 1.7 0.72 Tricuspid annular plain systolic excursion (mm) 22 ± 3.2 22 ± 3.5 22 ± 2.4 0.89 Pulmonary acceleration time (s) 111 ± 19.9 107 ± 19.9 124 ± 14.9 0.11 Systolic pulmonary artery pressure (mmHg) 26 ± 8.7 26 ± 9.2 26 ± 7.8 0.95 | Indexed left-ventricular end-diastolic volume (ml/m ²) | 47 ± 11.5 | 47 ± 12.2 | 46 ± 10.3 | 0.69 |
| Left-ventricular end-diastolic pressure E/e' 8.6 ± 2.6 9.2 ± 2.6 6.7 ± 1.6 < 0.0 Isovolumetric relaxation time (s) 69 ± 19.4 65 ± 18.6 82 ± 18.4 0.17 Mitral annular plain systolic excursion (mm) 12 ± 2.2 12 ± 2.3 13 ± 1.7 0.72 Tricuspid annular plain systolic excursion (mm) 22 ± 3.2 22 ± 3.5 22 ± 2.4 0.89 Pulmonary acceleration time (s) 111 ± 19.9 107 ± 19.9 124 ± 14.9 0.11 Systolic pulmonary artery pressure (mmHg) 26 ± 8.7 26 ± 9.2 26 ± 7.8 0.95 | Left-ventricular ejection fraction (%) | 62 ± 6.5 | 63 ± 6.7 | 58 ± 4.9 | 0.16 |
| Isovolumetric relaxation time (s) 69 ± 19.4 65 ± 18.6 82 ± 18.4 0.17 Mitral annular plain systolic excursion (mm) 12 ± 2.2 12 ± 2.3 13 ± 1.7 0.72 Tricuspid annular plain systolic excursion (mm) 22 ± 3.2 22 ± 3.5 22 ± 2.4 0.89 Pulmonary acceleration time (s) 111 ± 19.9 107 ± 19.9 124 ± 14.9 0.11 Systolic pulmonary artery pressure (mmHg) 26 ± 8.7 26 ± 9.2 26 ± 7.8 0.95 | E/A ratio | 0.95 ± 0.3 | 0.88 ± 0.2 | 1.15 ± 0.3 | 0.15 |
| Mitral annular plain systolic excursion (mm) 12 ± 2.2 12 ± 2.3 13 ± 1.7 0.72 Tricuspid annular plain systolic excursion (mm) 22 ± 3.2 22 ± 3.5 22 ± 2.4 0.89 Pulmonary acceleration time (s) 111 ± 19.9 107 ± 19.9 124 ± 14.9 0.11 Systolic pulmonary artery pressure (mmHg) 26 ± 8.7 26 ± 9.2 26 ± 7.8 0.95 | Left-ventricular end-diastolic pressure <i>E/e'</i> | 8.6 ± 2.6 | 9.2 ± 2.6 | 6.7 ± 1.6 | < 0.05 |
| Tricuspid annular plain systolic excursion (mm) 22 ± 3.2 22 ± 3.5 22 ± 2.4 0.89 Pulmonary acceleration time (s) 111 ± 19.9 107 ± 19.9 124 ± 14.9 0.11 Systolic pulmonary artery pressure (mmHg) 26 ± 8.7 26 ± 9.2 26 ± 7.8 0.95 | Isovolumetric relaxation time (s) | 69 ± 19.4 | 65 ± 18.6 | 82 ± 18.4 | 0.17 |
| Pulmonary acceleration time (s) 111 ± 19.9 107 ± 19.9 124 ± 14.9 0.11 Systolic pulmonary artery pressure (mmHg) 26 ± 8.7 26 ± 9.2 26 ± 7.8 0.95 | Mitral annular plain systolic excursion (mm) | 12 ± 2.2 | 12 ± 2.3 | 13 ± 1.7 | 0.72 |
| Systolic pulmonary artery pressure (mmHg) 26 ± 8.7 26 ± 9.2 26 ± 7.8 0.95 | Tricuspid annular plain systolic excursion (mm) | 22 ± 3.2 | 22 ± 3.5 | 22 ± 2.4 | 0.89 |
| | Pulmonary acceleration time (s) | 111 ± 19.9 | 107 ± 19.9 | 124 ± 14.9 | 0.11 |
| COVID-19 $(n=14)$ COVID-19: severe $(n=10)$ COVID-19: mild $(n=4)$ p va | Systolic pulmonary artery pressure (mmHg) | 26 ± 8.7 | 26 ± 9.2 | 26 ± 7.8 | 0.95 |
| | | COVID-19 $(n = 14)$ | COVID-19: severe $(n=10)$ | COVID-19: mild $(n=4)$ | p value |
| Global longitudinal strain (%) -19.7 ± 3.1 -19.6 ± 3.1 -20.0 ± 3.5 0.88 | Global longitudinal strain (%) | -19.7 ± 3.1 | -19.6±3.1 | -20.0 ± 3.5 | 0.88 |



Table 1 (continued)

| | COVID-19 $(n = 14)$ | COVID-19: severe $(n=10)$ | COVID-19: mild $(n=4)$ | p value |
|---|---------------------|---------------------------|------------------------|---------|
| Global radial strain: apical (%) | 43.0 ± 18.3 | 40.7 ± 20.3 | 50.7 ± 6.7 | 0.21 |
| Global radial strain: basal (%) | 35.7 ± 20.1 | 34.6 ± 22.0 | 41 ± 0.0 | 0.38 |
| Global circumferential strain: apical (%) | -18.5 ± 3.7 | -18.2 ± 3.7 | -19.3 ± 4.5 | 0.72 |
| Global circumferential strain: basal [%] | -10.8 ± 5.3 | -10.2 ± 5.7 | -13.5 ± 2.1 | 0.23 |
| Rotation apical (°) | 10.0 ± 8.6 | 11.9 ± 7.8 | 3.6 ± 9.7 | 0.28 |
| Rotation basal (°) | -5.4 ± 6.1 | -5.2 ± 6.5 | -6.5 ± 4.9 | 0.78 |
| Right-ventricular GLS (%) | -26.9 ± 5.8 | -26.6 ± 5.9 | -27.5 ± 6.1 | 0.76 |

Furthermore, patients were divided into two subgroups with respect to pulmonary condition (severe—need of mechanical or non-invasive ventilation vs. mild/moderate—no need of mechanical or non-invasive ventilation)

COVID-19 coronavirus disease, GLS global longitudinal strain

Mean values \pm standard deviation and numerical (percentage) distribution are shown. Statistical significance was accepted for p value of < 0.05

Tracking areas were adjusted to enable full myocardial tracking excluding epicardial as well as valvular or atrial structures. Complete deformation analysis could be performed in 14 patients—one patient was excluded due to left bundle branch block (LBBB) and three due to insufficient image quality. All excluded patients belonged to the patient group with severe symptoms (Table 2).

Statistical analysis

All statistical analyses were performed using SPSS Statistics version 24.0 (IBM, Armonk, NY). Continuous variables were expressed as mean value \pm standard deviation (SD) and were compared between groups using Student's t test. Statistical significance was accepted for p value < 0.05. Intra-observer variability and inter-observer (by another investigator blinded to each other's results) variability were assessed in five patients.

Results

Characteristics of all SARS-CoV-2-infected patients are presented in Table 1. Troponin T, NT-pro-BNP, C-reactive protein (CrP), procalcitonin (PCT), interleukin-6 (IL-6), and D-dimer were significantly increased in patients with severe in comparison to those with mild/moderate symptoms (Table 1). Cardiac dimensions and function assessed by conventional TTE were within normal ranges except LVRI (Table 1). In patients with severe symptoms, *E/E'*

was significantly higher in comparison to those with mild/moderate symptoms. RV echocardiographic parameters were not significantly different between both groups (Table 1). However, GLS of the free RV wall was mildly reduced (RV GLS: between -17 and -23%) in four patients with severe symptoms needing mechanical ventilation. All of these four patients showed elevated Troponin T- and NT-pro-BNP values. In all the other patients with severe symptoms, normal mean RV GLS values of at least -28% were observed. In addition, two patients with mild symptoms also showed mildly reduced RV GLS (between -22 and -23%).

In contrast to conventional echocardiography, deformation imaging (n=14) revealed several interesting findings potentially documenting myocardial involvement in SARS-CoV-2-infected patients with mild/moderate and severe symptoms (Table 2; Figs. 1, 2):

- 1. rLS was reduced in more than one of the basal LV segments—predominantly within the subepimyocardium documented by layer-strain analysis (n = 10/14 patients, 71%).
- 2. rRS curves showed biphasic pattern with maximum post-systolic rRS (= early systolic LV wall thinning) or a negative systolic rRS (= complete systolic LV wall thinning) (n=5/14 patients, 36%).
- 3. Absence or dispersion of basal rotation was observed (n=6/14 patients, 43%).
- 4. rCS was severely reduced or was positive in more than one of LV segments—predominantly in the mid and basal LV segments (n=7/14 patients, 50%).



Table 2 Analyses of myocardial deformation in SARS-CoV-2-infected patients

| | | rLS (C1) | LV GLS rRS apic (C2) | rRS apical (C2) | GRS apical | Rota- tion apical | Mean rotation apical | rCS apical (C3) | GCS | rRS basal (C2) | GRS basal | Rota- tion basal (C4) | Mean rotation basal | rCS basal (C3) | GCS | Twist (C5) | Rota- tion rate (C6) | RV GLS |
|----------------|----------------|----------------------|----------------------|-----------------------|---------------|-------------------------|----------------------------|-----------------------|------|----------------------|--------------|--------------------------------|---------------------------|----------------------|--------------|------------|----------------------------|--------|
| 1 | MechV | MechV il, al (basal) | - 16 | Norm | <i>L</i> 9 | Norm | 6 | Path a | -17 | Path | 14 | Norm | 8- | Norm | - 14 | Norm | Norm | -29 |
| 2 | MechV | MechV il (basal) | - 19 | Norm | 38 | Norm | 15 | Norm | -22 | Norm | 62 | Path | -3 | Path 1 | -15 | Norm | Norm | -31 |
| 3^a | MechV | a, al (basal) | - 17 | Norm | 31 | Path | ∞ | Path a | -15 | Norm | 46 | Path | 2 | Path a, al | 0 | Path | | -18 |
| 4 _b | MechV a, al (m | a, al (mid-basal) | - 23 | I | 1 | I | I | I | I | I | I | 1 | I | ı | ı | I | ı | -17 |
| 5 | NIV | a, as, is (basal) | - 19 | Norm | 37 | Norm | 13 | Norm | -23 | Path | - 16 | Path | 4 | Path i, il, al | -111- | Path | Path | -32 |
| ф | NIV | i, al, a (basal) | - 15 | ı | ı | ı | ı | ı | ı | 1 | ı | I | ı | ı | 1 | ı | 1 | |
| 7 | O_2 | as (basal) | - 26 | Path | 18 | Norm | 13 | Norm | -16 | Path | 36 | Norm | 8 - | Path il | -15 | Norm | Norm | -29 |
| ∞ | O_2 | as, al (basal) | - 20 | Norm | 73 | Norm | 13 | Norm | -21 | Path | 44 | Path | 9 | Path i, il, al | - 13 | Path | Path | -30 |
| 9 | 0 0 | il, al (basal) | -23 | Norm | 99 | Norm | 19 | Norm | -23 | Norm | 49 | Norm | -12 | Path 1 | -17 | Path | Path | -35 |
| 1 1 | O ² | aI (basal) | -21 | Norm | 22 | Path | 7- | Path a, as | -13 | Norm | 36 | Norm | -13 | Path il, al, a | <u>&</u> | Norm | Norm | -21 |
| 12 | O_2 | Is (basal) | - 19 | Norm | 30 | Norm | 41 | Path is, as | -15 | Norm | 28 | Norm | -12 | Ξ | 4- | Norm | Norm | -23 |
| 13 | O_2 | a, as, is (basal) | -21 | Norm | 25 | Norm | 22 | Norm | -17 | Norm | 47 | Path | 0 | Path il, al, a | -5 | Path | Path | -28 |
| 14^{b} | O_2 | ı | ı | ı | ı | ı | ı | ı | ı | ı | ı | I | ı | 1 | ı | I | ı | ı |
| 15 | ı | il (basal) | - 18 | Norm | 45 | Norm | 12 | Norm | -15 | Norm | 41 | Norm | -10 | Path a | -12 | Norm | Norm | -22 |
| 16^{a} | 1 | as, is (basal) | - 18 | Norm | 49 | Path | | Norm | -24 | Norm | 41 | Path | -3 | Path il | -15 | Path | Path | -33 |
| 17 | ı | as, is (basal) | - 24 | Norm | 58 | Path | 9 | Norm | - 19 | Path | 24 | Norm | -16 | Path i, il | -3 | Path | Path | -23 |
| 18 | 1 | Norm | - 24 | Norm | 30 | Path | 2 | Norm | - 19 | Norm | 31 | Norm | -13 | Path il | -16 | Path | Path | -33 |

Findings of regional longitudinal strain (rLS), left-ventricular global longitudinal strain (LV GLS), regional radial strain of apical left-ventricular (LV) segments (rRS apical), global radial strain of apical LV segments (GRS apical), apical rotation, mean apical rotation, regional circumferential strain of apical LV segments (rCS apical), global circumferential strain of apical LV segments GCS apical), regional radial strain of basal left-ventricular (LV) segments (rRS basal), global radial strain of basal LV segments (GRS basal), basal rotation, mean basal rotation, regional circumferential strain of basal LV segments (rCS basal), global circumferential strain of basal LV segments (GCS basal), twist, rotation rate, and global longitudinal strain of the free right-ventricular wall (RV GLS)


LV segments are labeled by a anterior, as anteroseptal, I inferior, il inferolateral, is inferoseptal and al anterolateral. MechV mechanical ventilation, NIV non-invasive ventilation, O2 oxygen supply via mask, path pathological finding, norm normal finding, C1 pathological criterium 1 described by qualitative alterations (see "Results"), C2 pathological criterium 2, C3 pathological criterium 3, C4 pathological criterium 4, C5 pathological criterium 5, C6 pathological criterium 6

^aPatients with CMR

^bPatients with insufficient image quality

Patient with left bundle branch block (LBBB)







- **<**Fig. 1 Longitudinal deformation pattern of a SARS-CoV-2-infected patient with severe symptoms: regional peak systolic longitudinal strain values are presented in the apical long axis (**a** aLAX), 2- (**b** 2ChV) and 4-chamber view (**c** 4ChV). Below regional left-ventricular (LV) longitudinal strain (rLS) curves of subepimyocardial (**d**, **g**, **j**), full myocardial (**e**, **h**, **k**) and subendomyocardial tracking (**f**, **i**, **l**) of the aLAX (**d**−**f**), 2- (**g**−**i**) and 4-ChV (**j**−**l**) show reduced basal rLS values. Subepimyocardial (*m*), full myocardial (*n*), and subendomyocardial (*o*) LS bull's eye patterns and corresponding LS values (*p*−*r*) are shown with predominantly reduced rLS inferolateral, anterolateral, and anterior
- 5. The net rotation showed a late post-systolic twist or a biphasic pattern (n = 8/14 patients, 57%).
- 6. The net-rotation curve showed an undulating polyphasic pattern during systole and/or higher maximum net values during diastole than during systole (= "chaotic" undulating diastolic pattern) (*n* = 8/14 patients, 57%).

The last two criteria can only be used, if rotation of the apical segments could have been correctly analyzed. Thus, the first four criteria can be classified as major criteria. Pathological deformation (> 2 major criteria) was observed in 13 of 14 (93%) SARS-CoV-2-infected patients and in all patients with severe symptoms (Fig. 3). Most of them presented comparable patterns of LV dysfunction similar to LV distribution of a "reverse basal tako-tsubolike syndrome" (n=7 with severe, n=1 with mild/moderate symptoms).

In 5 of 14 (36%) COVID-19 patients, the qualitative pattern of rRS was abnormal showing no alteration of LV wall thickness or in some cases even wall thinning (Figs. 4, 5). The alterations of rRS were often associated with rotation abnormalities (Figs. 4, 5).

Abnormal rCS was most often observed in the inferior, and infero- and anterolateral basal LV segments showing lengthening of the respective LV segments during systole (n = 7/14 patients, 50%) (Figs. 4, 5). Abnormal rCS was usually observed in all layers. Abnormal rCS of the subepimyocardial layers was rarely observed (n = 3/14 patients, 21%). CS was abnormal in 90% of patients with severe symptoms (n = 9/10), mostly with transmural involvement.

Twist and untwisting patterns—documented by net rotation and net-rotation rate—were abnormal due to impaired rotation of basal LV segments (Figs. 4, 5). Surprisingly, qualitative abnormal deformation patterns were also found in 3 of 4 (75%) patients with only mild/moderate symptoms (Table 2).

In two patients (one with severe and one with mild/moderate symptoms), echocardiographic findings could be confirmed by CMR (Fig. 6) illustrating regional edema and delayed enhancement predominantly in basal/mid LV segments as well as by impaired basal LV rotation in tagging sequences.

The importance of the described echocardiographic findings in SARS-CoV-2-infected patients is underlined by the comparison with data sets of age-matched controls (n=20) showing normal findings of LV deformation in all healthy individuals (Table 3). Schemes of normal LV deformation graphs are illustrated in Fig. 5. Normal curves of rRS, rCS, and LV rotation of a representative healthy individual are shown in Fig. 7.

Discussion


The main findings of the present study are:

- 1. Despite normal LVEF, most of SARS-CoV-2-infected patients showed abnormal LV deformation.
- 2. In patients with SARS-CoV-2 infection, especially basal LV segments seem to be affected. rRS, rCS, and rotation curves show abnormal patterns that may be described as "basal reverse tako-tsubo like-syndrome".
- 3. Basal circumferential LV myocardial involvement was usually transmural.
- 4. Abnormal deformation patterns were also observed in SARS-CoV-2-infected patients with mild/moderate symptoms.

Detection of acute myocarditis by echocardiography

In several case reports, speckle tracking is described as a useful tool to diagnose AM [22–25]. However, CMR is still the gold standard to diagnose AM according to Lake Louise criteria and T1-/T2-mapping [17, 18]. In AM induced by cardiotropic viruses, e.g., coxsackie, echo, influenza, Epstein–Barr, etc., myocardial damage is predominantly observed in the subepimyocardial layers, as documented by CMR and necropsy studies [17, 18, 26]. In AM induced by hyperinflammation or cytokine storm, transmural involvement can be observed [6]. In general, AM is characterized by a very high variability of myocardial involvement resulting in various patterns of myocardial deformation with respect to localization, myocardial transmurality, and/or AM severity







◄Fig. 2 Rotational deformation pattern of the same SARS-CoV-2-infected patient with COVID-19 pulmonary disease as in Fig. 1: normal radial strain patterns are documented in apical (a) and basal (b) left-ventricular (LV) segments. Apical rotation was also normal (c), whereas basal rotation showed a regional dispersion with almost no rotation septal and anterior (d, white arrow). Below parasternal short-axis views with segmental subendomyocardial (e, g) and subepimyocardial (f, h) circumferential strain values, strain curves, and color-M-Modes are shown. Abnormal deformation is documented in basal anterior, anterolateral, and inferolateral (g, h white arrows). Line graphs of apical (blue) and basal rotation (magenta) as well as net rotation (twist) (white) (i) and corresponding line graphs of rotation rate (j) document abnormal twist (biphasic apical rotation, i white arrows) and normal untwisting (j)

[27–29]. Furthermore, different viral infections may affect different myocardial structures within the LV wall architecture probably inducing characteristic deformation patterns.

Longitudinal deformation is mainly described by subendomyocardial, circumferential deformation, and rotation mainly by subepimyocardial layers [29–31]. It has to be considered that inner LV layers do significantly more contribute to the overall contraction than outer layers. The problem of AM detection by echocardiographic LV deformation—especially at early stages—is the predominant myocardial involvement of the outer quarter subepimyocardium, which only contributes about 10% to the overall contraction. Thus, in suspected AM, normal LV systolic function will be observed if it will be analyzed by LVEF or longitudinal deformation, e.g. GLS.

Although RV GLS was mildly reduced (between -17 and -23%) in four patients with severe and two patients with mild/moderate symptoms in comparison to reported normal mean vales of RV GLS (28.5 \pm 4.8), RV GLS was at least in line with the lowest expected value for patients < 50 years in all 18 patients with SARS-CoV-2-infection [32, 33]. It can be assumed that RV function might be earlier impaired in patients with AM due to the thinner RV wall. The reduction of RV function is known as a prognostic factor in SARS-CoV-2-infected patients [34, 35].

The analysis of LV deformation including circumferential strain and rotation may improve the echocardiographic diagnostic approach in AM [24, 27, 28]. However, the use of myocardial deformation is not yet widely implemented in patients with AM [36, 37]. Recently, the authors of the present study demonstrated the feasibility to define deformation

patterns for radial and circumferential strain as well as rotation in a cohort of healthy volunteers and professional athletes [19]. As also performed in the present study, several prerequisites have to be considered during image acquisition and post-processing analyses to exclude artifacts; for example, the acquisition of standardized short-axis views perpendicular to LV long axis, the documentation of apical rotation at the apical third of the left ventricle, the adjustment of the tracking area to exclude paracardial structures, as well as parts of the mitral valve [37]. Furthermore, the results of rotational deformation need to be counterchecked by multiple documentations to differentiate artifacts from deformation abnormalities as sequelae of SARS-CoV-2-induced myocardial involvement. In the future, 3D voxel tracking might also represent a new option to analyze LV rotation in patients with insufficient parasternal acoustic window. However, the limited spatial resolution of 3D echocardiography is still challenging.

Is there a specific deformation pattern in SARS-CoV-2-induced myocarditis?

The present study suggests that SARS-CoV-2-induced AM may be detected by deformation abnormalities using speckle tracking echocardiography. SARS-CoV-2-induced myocardial involvement often shows specific LV deformation patterns due to pronounced edema and/or myocardial damage in basal LV segments. Normal global longitudinal deformation and abnormal basal rLS underline the assumption that the early stage of SARS-CoV-2-induced myocarditis is characterized by a subepimyocardial involvement. Furthermore, abnormalities of basal rRS and rCS suggest a primarily basal subepimyocardial involvement. Transmural myocardial involvement obtained by circumferential strain analysis may indicate an advanced stage of the disease at the time of investigation. Comparable to Fabry and Friedreich disease [38, 39], SARS-CoV-2- induced myocardial involvement was predominantly observed in the basal/mid infero-/anterolateral LV segments, which could be partially explained by a pronounced—presumably hydrostatic—edema formation due to the supine position of the patient. The finding of a "reverse basal tako-tsubo-like syndrome" of basal LV segments might also be explained by the edema, which leads to abnormal basal rRS curves without any alterations



Fig. 3 Rotational deformation pattern in another SARS-CoV-2-infected patient with severe symptoms: normal radial strain patterns are documented in apical (a), whereas abnormal patterns are shown in basal (b) left-ventricular (LV) segments. Apical rotation was also normal (c), whereas basal rotation showed a regional dispersion with inverse rotation in various LV segments (d, white arrows). Below parasternal short-axis views with segmental subendomyocardial (e, g) and subepimyocardial (f, h) circumferential strain values, strain curves, and color-M-Modes are shown. Abnormal deformation is documented basal inferior, inferolateral, and anterolateral (g, h white arrows). Line graphs of apical (blue) and basal rotation (magenta) as well as net rotation (twist) (white) (i) and corresponding line graphs of rotation rate (j) document abnormal basal rotation with compensated twist by pronounced apical rotation (i white arrows) and a "chaotic" pattern of net-rotation rate during diastole (j)








Fig. 4 Scheme of longitudinal and radial (a, b) and apical (c, d) and basal (e, f) circumferential and rotational left-ventricular (LV) deformation under normal conditions (a, c, e) and in patients with SARS-CoV-2-infection (b, d, f). Normal changes of longitudinal strain (LS) are documented by longitudinal LV shortening (†) and normal changes of radial strain (RS) by LV wall thickening (↔) (a). In patients with SARS-CoV-2-infection, regional LS and RS are reduced (b). In comparison to normal conditions (e), basal circumferential strain (CS-black arrows) and clockwise rotation (colored arrows) are severely reduced in patients with SARS-CoV-2 infection (f). In addition, especially basal rRS is reduced (↔) in patients with SARS-CoV-2 infection (f)









▼Fig. 5 Overview of typical echocardiographic examples of abnormal deformation criteria in SARS-CoV-2-infected patients (left column) including representative schemes (mid column) and description (right column): reduced regional longitudinal strain predominantly in basal LV segments (a), reduced radial strain predominantly in basal LV segments (b), absence or dispersion of basal rotation (c), regional positive circumferential strain predominantly mid/basal lateral and anterior (d), biphasic net rotation (e), and polyphasic curves during systole, higher maximum, and "chaotic" curves of net-rotation rate during diastole (f)

during systole [15]. Comparing SARS-CoV-2-induced LV deformation patterns with the corresponding CMR findings in the present study, different LV deformation patterns are observed in comparison to AM patients caused by other cardiotropic viruses [17, 18, 40].

Interestingly, abnormal LV deformation patterns were still observed in all three patients after recovery from the acute stage indicating residual myocardial involvement. Furthermore, CMR showed late enhancement predominantly in the basal inferolateral/anterolateral LV segments indicating myocardial fibrosis or scars, respectively. Myocardial fibrosis might serve as potential arrhythmogenic substrates in long-term follow-up of SARS-CoV-2-induced AM patients. In consequence, CMR follow-up may be considered for patients after SARS-CoV-2-infection, who still show at least two major criteria of LV deformation abnormalities to assess residual scar formation or myocardial fibrosis.

The observations of pathological mid basal rotational LV deformation patterns in a high percentage of

SARS-CoV-2-infected patients seem to be important, but are obviously not a proof of a specific myocardial involvement in these patients.

The main limitation of the present study is the relatively small number of patients. 3D echocardiography could not routinely be performed at the isolation wards. Due to the evolving situation, the data of follow-up and CMR are limited and should be considered hypothesis generating. The strengths of the present study are the new findings of myocardial involvement due to abnormalities of LV deformation obtained by modern echocardiography in patients with SARS-CoV-2. However, the data about patients with SARS-CoV-2-infection should be interpreted carefully, because differences between percentage observations within the respective (sub)groups cannot show statistical significance.

Conclusions

Myocardial involvement due to SARS-CoV-2-induced AM might be characterized by specific LV deformation patterns—even in patient with mild/moderate symptoms. The detection of myocardial involvement by speckle tracking echocardiography is feasible at the acute stage of COVID-19 which may improve the early detection of myocardial involvement, risk stratification, and potentially cardio-protective treatment. Speckle tracking echocardiography might also be suitable to detect residual myocardial involvement after acute stage of SARS-CoV-2-infection. The present study sets the stage for follow-up studies to determine the prognostic value of these alterations in patients with SARS-CoV-2 infection.



Fig. 6 CMR findings of the same SARS-CoV-2-infected patient with COVID-19 pulmonary disease as in Fig. 1: BTFE images of long-axis view (LAX-a, d), twochamber view (2-ChV—b, e) and four-chamber view (4ChV—c, f) during diastole (a-c) and systole (d-f). T2STIR sequences of apical (g), mid (h), and basal (i) short-axis views (SAX). Edema is pronounced mid/basal septal-anterior (white arrows). Representative images of T1-(j), T2-mapping (k), and T1-mapping after contrast (1); PSIR sequences of mid/basal SAX views (m-o) documenting regional patchy late enhancement predominantly lateral (white arrows). Scar-T1TFE images of LAX (p), 2-ChV (q), and 4-ChV (r) document late enhancement mid/basal inferolateral (p), inferior (q), and anterolateral (r). Tagging images (s-v) of apical (s, t)and basal SAX (u, v) document abnormal basal rotation







Table 3 Analyses of myocardial rotational LV deformation in a control group of healthy individuals (n=20)

| Parameter | LV segments (myocardial layers) | Mean values ± SD |
|--------------|---|------------------|
| GRS (%) | Apical LV segments | 31.4±7.1 |
| Rotation (°) | Apical LV segments | 5.9±2.7 |
| GCS (%) | Apical LV segments (subepimyocardial layers) | -16.4 ± 4.8 |
| GCS (%) | Apical LV segments (subendomyocardial layers) | -36.2 ± 7.4 |
| GRS (%) | Basal LV segments | 30.0 ± 6.7 |
| Rotation (°) | Basal LV segments | -6.2 ± 2.8 |
| GCS (%) | Basal LV segments (subepimyocardial layers) | -15.3 ± 4.1 |
| GCS (%) | Basal LV segments (subendomyocardial layers) | -34.5 ± 5.4 |
| | | |

Mean values of radial and circumferential strain as well as rotation of the apical and basal LV segments are shown: global radial strain of apical LV segments (GRS apical), apical LV segments (GRS basal), basal rotation, and global circumferential strain of basal LV segments (GRS basal), basal rotation, and global circumferential strain of basal LV segments (GRS basal)







◄Fig. 7 Rotational deformation pattern of a healthy individual: radial strain patterns in apical (a) and basal (b) left-ventricular (LV) segments as well as apical (c) and basal rotation (d) are documented. Below parasternal short-axis views with apical (e, f) and basal (g, h) segmental subendomyocardial (e, g) and subepimyocardial (f, h) circumferential strain values, strain curves, and color-M-Modes are shown. Line graphs of apical (blue) and basal rotation (magenta) as well as net rotation (twist) (white) (i) and corresponding line graphs of rotation rate (j) document normal findings

Acknowledgements Open Access funding provided by Projekt DEAL. This paper is dedicated to our friend Maurizio Galderisi, professor at the Federico II University of Naples, Naples (Italy), who lost his life to COVID-19 in March 2020 (Stephan Stöbe, Andreas Hagendorff).

Funding None.

Compliance with ethical standards

Conflict of interest The authors declare that they have no conflict of interest.

Ethics approval The study complies with the Declaration of Helsinki and the study design was approved by the locally appointed ethics committee (359/18-ek).

Consent to participate and to publish Informed consent was obtained from all individual participants included in the study. Patients signed informed consent regarding publishing their data.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

References

- Akhmerov A, Marbán E (2020) COVID-19 and the heart. Circ Res 126:1443–1445
- Groß S, Jahn C, Cushman S, Bär C, Thum T (2020) SARS-CoV-2 receptor ACE2-dependent implications on the cardio-vascular system: from basic science to clinical implications. J Mol Cell Cardiol 144:47–53
- 3. Guzik TJ, Mohiddin SA, Dimarco A, Patel V, Savvatis K, Marelli-Berg FM et al (2020) COVID-19 and the cardiovascular system: implications for risk assessment, diagnosis, and treatment options. Cardiovasc Res cvaa106
- Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y et al (2020) Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 395:497–506
- Zheng YY, Ma YT, Zhang JY, Xie X (2020) COVID-19 and the cardiovascular system. Nat Rev Cardiol 17:259–260

- 6. Chen C, Zhou Y, Wang DW (2020) SARS-CoV-2: a potential novel etiology of fulminant myocarditis. Herz 45:1–3
- Inciardi RM, Lupi L, Zaccone G, Italia L, Raffo M, Tomasoni D et al (2019) Cardiac involvement in a patient with coronavirus disease 2019 (COVID-19). JAMA Cardiol. https://doi. org/10.1001/jamacardio.2020.1096
- Kang Y, Chen T, Mui D, Ferrari V, Jagasia D, Scherrer-Crosbie M et al (2020) Cardiovascular manifestations and treatment considerations in covid-19. Heart 106:1132–1141
- Kim IC, Kim JY, Kim HA, Han S (2020) COVID-19-related myocarditis in a 21-year-old female patient. Eur Heart J 41:1859
- Paul JF, Charles P, Richaud C, Caussin C, Diakov C (2020) Myocarditis revealing COVID-19 infection in a young patient. Eur Heart J Cardiovasc Imaging jeaa107
- Rizzo P, Vieceli Dalla Sega F, Fortini F, Marracino L, Rapezzi C, Ferrari R (2020) COVID-19 in the heart and the lungs: could we "Notch" the inflammatory storm? Basic Res Cardiol 115:31
- Siripanthong B, Nazarian S, Muser D, Deo R, Santangeli P, Khanji MY et al (2020) Recognizing COVID-19-related myocarditis: the possible pathophysiology and proposed guideline for diagnosis and management. Heart Rhythm. https://doi. org/10.1016/j.hrthm.2020.05.001
- Lippi G, Plebani M (2020) Laboratory abnormalities in patients with COVID-2019 infection. Clin Chem Lab Med. https://doi. org/10.1515/cclm-2020-0198
- Ruan Q, Yang K, Wang W, Jiang L, Song J (2020) Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China. Intensive Care Med 46:846–848
- Sala S, Peretto G, Gramegna M, Palmisano A, Villatore A, Vignale D (2020) Acute myocarditis presenting as a reverse takotsubo syndrome in a patient with SARS-CoV-2 respiratory infection. Eur Heart J 41:1861–1862
- Shi S, Qin M, Shen B, Cai Y, Liu T, Yang F et al (2020) Association of cardiac injury with mortality in hospitalized patients with COVID-19 in Wuhan. JAMA Cardiol, China. https://doi.org/10.1001/jamacardio.2020.0950
- Friedrich MG, Sechtem U, Schulz-Menger J, Holmvang G, Alakija P, Cooper LT et al (2009) Cardiovascular magnetic resonance in myocarditis: a JACC white paper. J Am Coll Cardiol 53:1475–1487
- Kotanidis CP, Bazmpani MA, Haidich AB, Karvounis C, Antoniades C, Karamitsos TD (2018) Diagnostic accuracy of cardiovascular magnetic resonance in acute myocarditis: a systematic review and meta-analysis. JACC Cardiovasc Imaging 11:1583–1590
- Döbel T, Stöbe S, Marshall RP, Hepp P, Fikenzer S, Fikenzer K et al (2020) Possible new options and benefits to detect myocarditis, right ventricular remodeling and coronary anomalies by echocardiography in systematic preparticipation screening of athletes. Int J Cardiovasc Imaging. https://doi.org/10.1007/s10554-020-01899-1
- Lang RM, Badano LP, Mor-Avi V, Afilalo J, Armstrong A, Ernande L et al (2015) Recommendations for cardiac chamber quantification by echocardiography in adults: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. J Am Soc Echocardiogr 8:1–39
- Nagueh SF, Smiseth OA, Appleton CP, Byrd BF, Dokainish H, Edvardsen T et al (2016) Recommendations for the evaluation of left ventricular diastolic function by echocardiography: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. J Am Soc Echocardiogr 29:277–314
- Caspar T, Fichot M, Ohana M, El Ghannudi S, Morel O, Ohlmann P (2017) Late detection of left ventricular dysfunction using



- two-dimensional and three-dimensional speckle-tracking echocardiography in patients with history of nonsevere acute myocarditis. J Am Soc Echocardiogr 30:756–762
- Løgstrup BB, Nielsen JM, Kim WY, Poulsen SH (2016) Myocardial oedema in acute myocarditis detected by echocardiographic 2D myocardial deformation analysis. Eur Heart J Cardiovasc Imaging 17:1018–1026
- Sturmberger T, Niel J, Aichinger J, Ebner C (2016) Acute myocarditis with normal wall motion detected with 2D speckle tracking echocardiography. Echo Res Pract 3:K15–K19
- Tünnemann-Tarr A, Stöbe S, Laufs U, Hagendorff A, Tayal B (2020) Speckle tracking echocardiography in a patient with viral myocarditis and acute myocardial infarction. J Cardiol Cases
- Shirani J, Freant LJ, Roberts WC (1993) Gross and semiquantitative histologic findings in mononuclear cell myocarditis causing sudden death, and implications for endomyocardial biopsy. Am J Cardiol 72:952–957
- Afonso L, Hari P, Pidlaoan V, Kondur A, Jacob S, Khetarpal V (2010) Acute myocarditis: can novel echocardiographic techniques assist with diagnosis? Eur J Echocardiogr 11:E5
- Hsiao JF, Koshino Y, Bonnichsen CR, Yu Y, Miller FA, Pellikka PA et al (2013) Speckle tracking echocardiography in acute myocarditis. Int J Cardiovasc Imaging 29:275–284
- Nakatani S (2011) Left ventricular rotation and twist: why should we learn? J Cardiovasc Ultrasound 19:1–6
- Stöhr EJ, Shave RE, Baggish AL, Weiner RB (2016) Left ventricular twist mechanics in the context of normal physiology and cardiovascular disease: a review of studies using speckle tracking echocardiography. Am J Physiol Heart Circ Physiol 311:H633–H644
- Torrent-Guasp F, Ballester M, Buckberg GD, Carreras F, Flotats A, Carrió I et al (2001) Spatial orientation of the ventricular muscle band: physiologic contribution and surgical implications.
 J Thorac Cardiovasc Surg 122:389–392
- 32. Morris DA, Krisper M, Nakatani S, Köhncke C, Otsuji Y, Belyavskiy E et al (2017) Normal range and usefulness of right ventricular

- systolic strain to detect subtle right ventricular systolic abnormalities in patients with heart failure: a multicentre study. Eur Heart J Cardiovasc Imaging 18:212–223
- Lee JH, Park JH (2018) Strain analysis of the right ventricle using two-dimensional echocardiography. J Cardiovasc Imaging 26:111–124
- Szekely Y, Lichter Y, Taieb P, Banai A, Hochstadt A, Merdler I et al (2020) The spectrum of cardiac manifestations in coronavirus disease 2019 (COVID-19)—a systematic echocardiographic study. Circulation 142:342–353
- Li Y, Li H, Zhu S, Xie Y, Wang B, He L et al (2020) Prognostic value of right ventricular longitudinal strain in patients with COVID-19. JACC Cardiovasc Imaging
- Johnson C, Kuyt K, Oxborough D, Stout M (2019) Practical tips and tricks in measuring strain, strain rate and twist for the left and right ventricles. Echo Res Pract 6:R87–R98
- Spriestersbach H, Oh-Icí D, Schmitt B, Berger F, Schmitz L
 (2015) The influence of the region of interest width on twodimensional speckle tracking-based measurements of strain and strain rate. Echocardiography 32:89–95
- Esposito R, Santoro C, Sorrentino R, Riccio E, Citro R, Buonauro A et al (2019) Layer-specific longitudinal strain in Anderson– Fabry disease at diagnosis: a speckle tracking echocardiography analysis. Echocardiography 36:1273–1281
- Weidemann F, Niemann M, Ertl G, Störk S (2010) The different faces of echocardiographic left ventricular hypertrophy: clues to the etiology. J Am Soc Echocardiogr 23:793–801
- Luetkens JA, Isaak A, Zimmer S, Nattermann J, Sprinkart AM, Boesecke C et al (2020) Diffuse myocardial inflammation in COVID-19 associated myocarditis detected by multiparametric cardiac magnetic resonance imaging. Circ Cardiovasc Imaging 13:e010897

